Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NPT088 in Probable Alzheimer's Disease
NCT03008161Phase 1Completed
- Sponsor
- Proclara Biosciences
- Start
- Dec 2016
- Primary completion
- Feb 2019
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NPT088 in Alzheimer's disease (AD) (4 cohorts), sponsored by Proclara Biosciences. Primary endpoint: Number of patients with adverse events at Week 32. Started Dec 2016; status: completed.
02
Drugs
NPT088
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03008161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03008161.